Hemiarthoplasty with a pyrolytic carbon humeral head yielded positive 2-year outcomes
Click Here to Manage Email Alerts
Key takeaways:
- Hemiarthroplasty with a pyrolytic carbon humeral head yielded positive 2-year clinical outcomes.
- The Aequalis Pyrocarbon humeral head (Stryker) is FDA approved and ready for use.
SCOTTSDALE, Ariz. — Presented results showed hemiarthroplasty with a pyrolytic carbon humeral head yielded positive 2-year clinical outcomes for patients with glenohumeral arthritis and proximal humeral avascular necrosis.
“[Pyrolytic carbon] is a ceramic deposition of carbon onto graphite that’s loaded with tungsten, so it can be seen on an X-ray and placed through a special tube that deposits carbon in crystalline form,” Armodios M. Hatzidakis, MD, said in his presentation at the American Shoulder and Elbow Surgeons Annual Meeting. “It’s biologically compatible as a hard surface with minimal wear and high resistance to scratching,” he added.
In a prospective, single-arm, multicenter study, Hatzidakis and colleagues analyzed 2-year clinical outcomes and radiographic implant survivorship in 157 patients (mean age of 52.1 years) who underwent hemiarthroplasty with the Aequalis Pyrocarbon humeral head (Stryker) between December 2015 and April 2017.
Clinical outcomes included pain scores, Constant scores, Single Assessment Numeric Evaluation (SANE) scores, EuroQol-5 D (EQ-5D) scores and American Shoulder and Elbow Surgeons scores. Researchers also analyzed a propensity score-matched control cohort of patients who underwent hemiarthroplasty with a cobalt chrome humeral head.
Overall, Hatzidakis and colleagues found statistically significant improvements across all clinical outcomes for patients who received the pyrolytic carbon head. Constant scores increased from 43.8 at baseline to 78.1 at 2-year follow-up, and researchers found no evidence of osteolysis, migration, component fracture or subsidence on radiographs at 2 years.
According to the abstract, 91% of patients were satisfied or very satisfied with their outcome and three patients required revision due to pain or loss of range motion. The propensity score-adjusted success rate was 82.7% for the pyrolytic carbon cohort and 66.8% for the cobalt chrome cohort.
Hatzidakis noted the Aequalis Pyrocarbon head is FDA approved and ready for use with hemiarthroplasty in this patient population.
Collapse
Hatzidakis AM, et al. Paper 35. Presented at: American Shoulder and Elbow Surgeons Annual Meeting; Oct. 4-7, 2023; Scottsdale, Ariz.
Read more about
Click Here to Manage Email Alerts